BeiGene (BGNE) Gets a Buy Rating from Morgan Stanley

Morgan Stanley analyst Matthew Harrison maintained a Buy rating on BeiGene (BGNEResearch Report) today and set a price target of $293.00. The company’s shares closed last Friday at $177.50.

According to, Harrison is a 5-star analyst with an average return of 7.4% and a 52.0% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, BioMarin Pharmaceutical, and Vertex Pharmaceuticals.

Currently, the analyst consensus on BeiGene is a Strong Buy with an average price target of $280.51.

See the top stocks recommended by analysts >>

The company has a one-year high of $426.56 and a one-year low of $118.18. Currently, BeiGene has an average volume of 295.7K.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BGNE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BeiGene, a biopharmaceutical company. The company primarily focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.

Read More on BGNE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More